The combined vaginal contraceptive ring, NuvaRing, and cerebral venous sinus thrombosis: A case report and review of the literature

Journal of Emergency Medicine

Volumn 42, Issue 4, 2012, Pages 413-416

  Kolacki, Christian ^a   Rocco, Vito ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

central venous sinus thrombosis; combined vaginal contraceptive ring; complications; NuvaRing

Indexed keywords

ETHINYLESTRADIOL PLUS ETONOGESTREL;

ADULT; BRAIN ANGIOGRAPHY; CASE REPORT; CEREBRAL SINUS THROMBOSIS; CEREBRAL VENOUS SINUS THROMBOSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; NAUSEA AND VOMITING; NECK PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOPHOBIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; RIGIDITY; SIGMOID SINUS THROMBOSIS;

EID: 84859715495     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2011.06.011     Document Type: Article

References (37)

1. Cardiovascular disease and steroid hormone contraception: report of a WHO scientific group World Health Organ Tech Rep Ser 877 1998 1 89
2. E.A. Atkinson, B. Fairburn, and K.W.G. Heathfield Intracranial venous thrombosis as complication of oral contraception Lancet 1 1970 914 918
3. D.S. Buchanan, and D.H. Brazinsky Dural sinus thrombosis and cerebral venous thrombosis. Incidence in young women receiving oral contraceptives Arch Neurol 22 1970 440 444
4. U. Scoditti, G. Buccino, M. Pini, C. Patacini, and D. Mancia Risk of acute cerebrovascular events related to low oestrogen oral contraceptive treatment Ital J Neurol Sci 19 1998 15 19
5. S.F. De Bruijn, J. Stam, M.M. Koopman, and J.P. Vandenbroucke Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and of who are carriers of hereditary prothrombotic conditions. The cerebral venous sinus thrombosis study group BMJ 316 1998 589 592
6. I. Martinelli, E. Sacchi, G. Landi, E. Taioli, F. Duca, and P.M. Mannucci High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives N Engl J Med 338 1998 1840 1841
7. S.S. Jick, and H. Jick Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives, and the contraceptive patch Contraception 74 2006 290 292
8. M. Sheerani, and M.Z.S. Urfy Oral contraceptives and cerebral venous thrombosis: case report and a brief review of the literature J Pak Med Assoc 56 2006 559 560
9. L.W. Hill, and F.M. Hindelang Cerebral venous thrombosis as a complication of oral contraceptive use in a 15-year-old patient: a case report La State Med Soc 159 2007 195 196
10. G. Buccino, U. Scoditti, M. Pini, A.R. Tagliaferri, C. Manotti, and D. Mancia Low-oestrogen oral contraceptives as a major risk factor for cerebral venous and sinus thrombosis: evidence from a clinical series Ital J Neurol Sci 20 1999 231 235
11. Organon, USA Inc. Full product information, including boxed warning; 2008. Available at: http://www.nuvaring.com/Consumer/Global/ prescribingInformation.asp. Accessed January 1, 2010.
12. K. Oddsson, B. Leifels-Fischer, and N.R. de Melo Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial Contraception 71 2005 176 182
13. H.J. Ahrendt, I. Nisand, and C. Bastianelli Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone Contraception 74 2006 451 457
14. R.I. Bjarnadottir, M. Tuppurainen, and S.R. Killick Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ ethinyl estradiol Am J Obstet Gynecol 186 2002 389 395
15. L.M. Lopez, D.A. Grimes, M.F. Gallo, and K.F. Schulz Skin patch and vaginal ring versus combined oral contraceptives for contraception Cochrane Database Syst Rev 3 2010 CD003552
16. F. Roumen, M.M.T. op ten Berg, and E.H.M. Hoomans The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands Eur J Contracept Reprod Health Care 11 2006 14 22
17. D.R. Mishell, M. Talas, and A.F. Parlow Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate Am J Obstet Gynecol 107 1970 100 107
18. N.J. Alexander, E. Baker, M. Kaptein, U. Karck, L. Miller, and E. Zampaglione Why consider vaginal drug administration? Fertil Steril 82 2004 1 12
19. M.W. Van den Heuvel, A.J.M. van Bragt, A.K.M. Alnabawy, and M.C.J. Kaptein Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive Contraception 72 2005 168 174
20. C.J. Timmer, and T.M.T. Mulders Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring Clin Pharmacokinet 39 2000 233 242
21. S. Veres, L. Miller, and B. Burington A comparison between the vaginal ring and oral contraceptives Am J Obstet Gynecol 104 2004 555 563
22. R. Sitruk-Ware, G. Plu-Bureau, and J. Menard Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study J Clin Endocrinol Metab 92 2007 2074 2079
23. M. Rad, C. Kluft, and J. Menard Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables Am J Obstet Gynecol 195 2006 72 77
24. K. Fleischer, H.A. van Vliet, F.R. Rosendaal, J. Rosing, S. Tchaikovski, and F.M. Helmerhorst Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study Thromb Res 123 2009 429 435
25. J.P. Vandenbrouke, J. Rosing, and K.W. Bloemnkamp Oral contraceptives and the risk of venous thrombosis N Engl J Med 344 2001 1527 1535
26. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Venous thromboembolic disease and combined oral contraceptives: results of international multi-centre case-control study Lancet 346 1995 1575 1582
27. J.M. Kemmeren, A. Algra, and D.E. Grobbee Third generation oral contraceptives and risk of venous thrombosis: meta-analysis BMJ 323 2001 119 120
28. W.O. Spitzer, M.A. Lewis, L.A. Heinemann, M. Thorogood, and K.D. MacRae Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transitional research group on oral contraceptives and the health of young women BMJ 312 1996 83 88
29. S.S. Jick, J.A. Kaye, S. Russmann, and H. Jick Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel Contraception 3 2006 56 70
30. H. Jick, S.S. Jick, V. Gurewich, M.W. Myers, and C. Vasilakis Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components Lancet 346 1995 1589 1593
31. S. Hennessy, J.A. Berlin, J.L. Kinman, D.J. Margolis, S.M. Marcus, and B.L. Strom Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis Contraception 64 2001 125 133
32. H.A.A.M. Van Vliet, M. Frolich, and M. Christella Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestins Hum Reprod 20 2004 563 568
33. S. Middledorp, J.C.M. Meijers, and A.E. van den Ende Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a crossover study Thromb Haemost 84 2000 4 8
34. J. Rosing, H.C. Hemker, and G. Tans Molecular biology and pathophysiology of APC resistance: current insights and clinical implications Semin Thromb Hemost 24 1998 329 335
35. M. Van Rooijen, A. Silveira, A. Hamsten, and K. Bremme Sex-hormone-binding globulin-a surrogate marker for the prothrombotic effects of combined oral contraceptives Am J Obstet Gynecol 190 2004 332 337
36. V. Odlind, I. Milsom, I. Persson, and A. Victor Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 81 2002 482 490
37. th edn. 2009 World Health Organization Geneva, Switzerland Available at: http://www.who.int/ reproductivehealth/publications/family-planning Accessed January 7, 2010